High-potency cannabis fuels state debates over psychosis and addiction risks

Amy Wadsworth’s son, once a healthy teenager, began using cannabis in college to cope with social anxiety and sleep issues. Within months, he experienced terrifying episodes, psychotic breaks, and a diagnosis of severe cannabis use disorder, drastically altering his life trajectory. Now 25, he has spent years in hospitals and treatment programs across the U.S. Research increasingly links frequent use of high-THC cannabis to higher risks of addiction, psychosis, and mental health issues, especially for adolescents and young adults. THC levels in legal cannabis products have surged from single digits to 15-20% in flowers and over 80% in concentrates like waxes and oils. About 15% of Americans aged 12+ used marijuana in 2024, with nearly 30% of users developing cannabis use disorder, according to federal health agencies. Public health experts argue perceptions of marijuana’s safety lag behind its evolving potency, despite federal reclassification of medical cannabis as less restrictive. Dr. Alta DeRoo, chief medical officer at Hazelden Betty Ford Foundation, warned that reducing cannabis’ legal restrictions without addressing potency risks undermines public health efforts. Connecticut lawmakers recently reinstated a 35% THC cap on cannabis flower after initially eliminating it, citing concerns over public health impacts. However, the same legislation expanded allowable THC levels in concentrates and other products, reflecting industry resistance and regulatory uncertainty. Similar debates over potency limits are unfolding in states like California and others, where lawmakers weigh health risks against market expansion. The cannabis industry opposes strict caps, arguing government overreach in a legal market. Meanwhile, states grapple with balancing public health warnings with economic incentives tied to legalization. Federal reclassification of cannabis as Schedule III has further complicated efforts to regulate potency, as it signals reduced perceived risk without addressing high-THC dangers.